Pathway Linked to Chemotherapy Resistance in Colorectal Cancer
Researchers have discovered a signaling pathway that helps colorectal cancer cells survive chemotherapy treatment.
Updated on Oct. 2, 2026 in Cancer
Scientists have identified a specific signaling axis that enables colorectal cancer cells to develop resistance to oxaliplatin, a common chemotherapy medication. This finding may offer a new target for enhancing treatment efficacy in the future.
Why it matters
Understanding how cancer cells evade chemotherapy is a critical step in overcoming treatment resistance. This discovery reveals how cellular stress responses allow tumors to survive, potentially guiding future therapeutic strategies.
A study published on October 2, 2026, in the journal Oncogene identified that the TFAM-mtDNA-STING-TBK1 signaling axis facilitates survival in colorectal cancer cells under oxaliplatin treatment. These results are preliminary and based on laboratory models.
The players
Oncogene
A peer-reviewed scientific journal that publishes research on cancer biology and experimental therapeutics.
The details
When treated with oxaliplatin, colorectal cancer cells experience mitochondrial damage, which releases mitochondrial DNA into the cytosol. This leakage activates the STING-TBK1 signaling pathway, which in turn enhances lysophagy, a process that clears damaged cell components to maintain survival. By inhibiting TBK1, researchers were able to reduce this lysophagic flux and restore the cancer cells sensitivity to the chemotherapy treatment.
Timeline
October 2, 2026: Study published in the journal Oncogene.
Health Landscape
This research follows a pattern set by the NCI-MATCH clinical trial, which seeks to identify and target specific molecular drivers of cancer to improve treatment responses. It adds to the growing scientific focus on how cellular stress pathways contribute to chemotherapy resistance.
These findings are currently limited to laboratory research and do not change standard colorectal cancer treatment protocols. Patients managing colorectal cancer should discuss their specific treatment plan and any questions about drug resistance with their oncologist.
The takeaway
The study suggests that targeting specific signaling pathways could eventually help overcome chemotherapy resistance. Patients should focus on maintaining open communication with their care team regarding their ongoing treatment and any side effects experienced.
Further reading
For more on the current research regarding tumor biology and treatment, visit our Cancer section.
Source note: This article includes information reported by Nature.
